There are multiple distinctions in labeling indications between biosimilars and brand products, and pharmacists must become familiar with these to be of maximum service to patients and physicians, according to a review.
The introduction of biosimilars in the US market brings along specific challenges to health system pharmacists, including formulary assessment, implementation, and education of patients and various health system stakeholders, according to a review published in Drugs In Context.
Despite the Biologics Price Competition and Innovation Act (BPCIA) being passed in 2009, the US FDA approved its first biosimilar in 2015. As of February 2020, 24 other biosimilars have been approved while only 11 have launched. In comparison, the European Union has had over 50 biosimilars approved since 2006.
Health system pharmacists ought to carefully review product labels of the biosimilar and its reference product (RP) to understand how differences can affect clinical practice and formulary decisions, researchers note. Some biosimilars and their reference products have differing storage and dosing requirements. “As multiple biosimilars for a given RP enter the market, these activities will become progressively more challenging,” authors said.
Changes in conventional naming practices also have to be taken into account and accurately reflected in electronic medical records. Mistakes in the transition to nonproprietary biologic names could result in errors involving inventory management, pharmacovigilance, and patient safety.
In the United States, an interchangeability designation can only be achieved independently from the initial approval of a biosimilar. Because of this, biosimilars may never achieve interchangeability. In the absence of the designation, “substitution may still occur but only with the documented prescriber, and possibly patient, notification and/or consent, as stipulated by state-level laws,” researchers said.
Visit AJMC.com for the full story.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
June 27th 2024Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.
Biosimilar Adoption in the UK: Patient and Consultant Views on Safety and Switching
June 26th 2024Lack of knowledge and confidence in biosimilars continues despite growing education efforts, impacting provider willingness to prescribe biosimilar medicines and patient perceptions about their treatment and switching to a biosimilar.